Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 9, 2024
– Advance-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in Q4 2024 –
– Ongoing Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uHTN or rHTN is anticipated to deliver topline data in 2H 2025 –
Read more at globenewswire.com10.52
-0.02 (-0.19%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
